GenVec, BTG USA Inc. deal

The companies will develop gene delivery systems based on BTG's Herpes simplex virus (HSV) technology to deliver genes to the brain. The technology introduces a modification into HSV's DNA, which blocks replication of the virus. The genetically modified HSV then can be used to express therapeutic genes. HSV can enter and persist in nervous system tissues, and therefore may be effective in delivering genes to treat neurological diseases, BTG said. ...